Enterol, 250 mg 10 pcs.
€13.08 €10.90
Pharmacotherapeutic group: Antidiarrheal.
ATX code: A07FA02
Pharmacological properties:
Pharmacodynamics
em>Saccharomyces boulardii CNCM I-745 is a live, non-pathogenic yeast (deposited at the National Collection of Cultures and Microorganisms (CNCM), International Depository, Institut Pasteur, Paris).
The drug Saccharomyces boulardii is a probiotic and acts in the gastrointestinal tract as an anti-diarrheal microorganism.
The pharmacodynamics of Saccharomyces boulardii have been studied in various models in in
– has antimicrobial action due to its antagonistic effect against pathogenic and conditionally pathogenic microorganisms: Clostridium difficile, Candida albicans, Candida krusei, Candida pseudotropicalis, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella typhimurium, Yersinia enterocolitica, Escherichia coli, Shigella dysenteriae, Staphylococcus aureus and others, and
– has an antitoxin effect against bacterial cyto- and enterotoxins;
– – increases intestinal enzymatic function;
– A component of the cell wall of Saccharomyces boulardii mannitol is a substrate for pathogenic strains of Escherichia coli and Salmonella typhimurium<
that causes their adhesion (attachment) to the surface of Saccharomyces boulardii and subsequent excretion from the body;
has a natural resistance to antibiotics.
Pharmacokinetics
Saccharomyces boulardii is not eubiotic, is not part of the microflora of the healthy human body. Saccharomyces boulardii is not absorbed, passes through the digestive tract unchanged, without colonization. The concentration of Saccharomyces boulardii in the intestine is maintained at a constant level during the period of administration of the drug. Saccharomyces boulardii is completely eliminated from the body within 2-5 days after discontinuation of the drug.
Indications
The treatment and prevention of diarrhea of any etiology in adults and children from 1 year old, including:
– intestinal dysbacteriosis (dysbiosis);
– acute infectious, viral or bacterial diarrhea;
– diarrhea caused by taking antibiotics (antibiotic-associated diarrhea);
– irritable bowel syndrome, enterocolitis;
– traveler’s diarrhea;
– diarrhea caused by Clostridium difficile, in combination with vancomycin or metronidazole therapy.
– adverse gastrointestinal reactions during eradication therapy with Helicobacter pylori.
Composition
Active ingredient: Saccharomyces boulardii CNCM I-745 lyophilizate 250.00 mg.
Auxiliary substances:lactose monohydrate, fructose, colloidal silicon dioxide, tutti-frutti flavoring.
How to take, the dosage
For oral administration.
Children from 1 to 3 years – 1 sachet twice a day.
Children from 3 years and adults – 1-2 sachets twice a day.
The contents of the sachet can be mixed with water or other beverage, or added to food or baby food bottle, just before taking.
Do not take with hot drinks or alcoholic beverages because of the risk of decreased activity and destruction of non-pathogenic yeast.
For the treatment of acute infectious, viral or bacterial diarrhea, the course of treatment is 5-10 days.
For prevention of antibiotic-associated diarrhea the course of treatment by days corresponds to the course of antibiotic use.
For prevention of diarrhea caused by Clostridium difficile in combination with vancomycin or metronidazole therapy, the course of treatment is 1 month.
For prevention of traveler’s diarrhea, the course of treatment by day corresponds to the duration of the trip.
To treat irritable bowel syndrome, the drug should be continued until symptoms disappear.
The treatment of acute diarrhea must always be accompanied by rehydration (drinking plenty of fluids).
Interaction
Special Instructions
If after two days of using Enterol® for treatment of acute diarrhea there is no improvement, as well as in case of fever, blood or mucus in stools, you should immediately contact a physician. A feeling of thirst and dry mouth are signs of inadequate rehydration (not drinking enough).
Due to the yeast nature of Enterol®, very rare cases of fungemia have been reported (cultures of Saccharomyces were isolated from the blood), mostly in patients who had a central venous catheter, in patients who were extremely ill or had immunodeficiency states, which was often accompanied by fever (elevated body temperature). In most cases, the outcome was satisfactory after discontinuation of treatment, administration of antifungal therapy, and removal of the catheter, if necessary. However, in some patients whose condition was severe, the outcome was unfavorable.
Particular caution should be exercised when handling the drug in the presence of patients with central and peripheral venous catheters, even if they are not treated with Enterol®, care should be taken to avoid the risk of contamination by contaminated hands or airborne spread of microorganisms.
Influence on driving and operating ability:
Enterol® does not affect the ability to drive or engage in other potentially dangerous activities requiring increased concentration and rapid psychomotor reactions.
Synopsis
Contraindications
High sensitivity to one of the components of the drug, allergy to yeast, especially to Saccharomyces boulardii.
Having a central venous catheter, patients in severe condition or with significant immune disorders due to risk of fungemia.
Lactose intolerance, lactase deficiency, congenital galactosemia,
glucose-galactose malabsorption syndrome.
Side effects
Skin and subcutaneous tissue disorders
Very rare: allergic reactions – itching, papular rash (urticaria), skin rash, local or distributed throughout the body (localized or generalized exanthema), facial edema (angioedema).
Disorders of the immune system
Very rare: anaphylactic reactions or anaphylactic shock.
Gastrointestinal tract disorders
Rarely: flatulence;
Frequent unknown: constipation.
Infectious and parasitic diseases
Very rarely: fungemia (in patients who have a central venous catheter installed, as well as in hospitalized patients, persons with immunodeficiency conditions (see section “Special indications”).
Overdose
Pregnancy use
Data on the use of Saccharomyces boulardii in pregnant women and during breastfeeding are lacking or limited.
Saccharomyces boulardii is not absorbed from the gastrointestinal tract.
As a precautionary measure, it is preferable to evaluate the benefit ratio of the drug to the possible risk before using the drug during pregnancy and breastfeeding.
Weight | 0.018 kg |
---|---|
Shelf life | 3 years. Do not use after the date indicated on the package. |
Conditions of storage | At 15 to 25 oC. Store out of the reach of children. |
Manufacturer | Biocodex, France |
Medication form | Powder for oral suspension |
Brand | Biocodex |
Other forms…
Related products
Buy Enterol, 250 mg 10 pcs. with delivery to USA, UK, Europe and over 120 other countries.